U.S. Court in Virginia Trims Whistleblower Action Alleging Fraudulent Best Price Reporting, But Allows FCA Conspiracy Claim
- October 18, 2023
A whistleblower can proceed with her claim that Indivior, Inc., which manufacturers the opioid addiction treatment Suboxone, conspired in violation of the False Claims Act (FCA) with pharmacy benefit manager Express Scripts to ensure favorable placement of the drug on its formulary for certain commercial plans through rebates designed to avoid Medicaid best price reporting obligations, a federal court in Virginia held October 17,
ARTICLE TAGS
You must be logged in to access this content.